Everything below concerns circadian clock. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-05-06. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
Osteoarthritis is a type of degenerative joint disease that results from breakdown of joint cartilage and underlying bone. A form of arthritis, it is believed to be the fourth leading cause of disability in the world, with an estimated 240 million people worldwide having activity-limiting osteoarthritis. The most common symptoms are joint pain and stiffness. Usually the symptoms progress slowly over years. Other symptoms may include joint swelling, decreased range of motion, and, when the back is affected, weakness or numbness of the arms and legs. The most commonly involved joints are the two near the ends of the fingers and the joint at the base of the thumbs, the knee and hip joints, and the joints of the neck and lower back. The symptoms can interfere with work and normal daily activities. Unlike some other types of arthritis, only the joints, not internal organs, are affected. Possible causes include previous joint injury, abnormal joint or limb development, and inherited factors. Risk is greater in those who are overweight, have legs of different lengths, or have jobs that result in high levels of joint stress. Osteoarthritis is believed to be caused by mechanical stress on the joint and low grade inflammatory processes. It develops as cartilage is lost and the underlying bone becomes affected. As pain may make it difficult to exercise, muscle loss may occur. Diagnosis is typically based on signs and symptoms, with medical imaging and other tests used to support or rule out other problems.
Thus, threatened states usually prefer buck-passing to balancing as the buck-passer avoids the costs of fighting the aggressor in the event of war. Some realists believe there is a strong tendency to buck-pass or free-ride within balancing coalitions themselves, usually leaving their alliance partners to assume the heavy burden of wearing down the enemy, leaving the free-rider's military fresh to win the final battles of the war and thus be in a better position to dictate the peace, such as the UK's light involvement in the early stages of World War I. Likewise, buck-passers can enter wars late after both sides have been worn down, allowing the buck-passer to dominate the post-war world. A potential drawback of the strategy occurs if the buck-catcher fails to check the aggressor, as the buck-passer will be in a much more vulnerable situation. Proponents of the theory point to the Soviet Union's role in World War II whereby it passed the buck to the UK and France through the Molotov–Ribbentrop Pact with Nazi Germany. After eliminating France the Germans had no Western front to divide their forces, allowing them to concentrate their forces against the USSR. According to a 2015 study, "the diplomatic record yields almost no examples of firm peacetime balancing coalitions over the past 200 years. When alliances have formed, great powers have generally doubted the reliability of their allies and of their opponents' allies."
Another early adopter of diesel–electric transmission was the US Navy, whose Bureau of Engineering proposed its use in 1928. It was subsequently tried in the S-class submarines S-3, S-6, and S-7 before being put into production with the Porpoise class of the 1930s. From that point onwards, it continued to be used on most US conventional submarines. Apart from the British U-class and some submarines of the Imperial Japanese Navy that used separate diesel generators for low speed running, few navies other than those of Sweden and the US made much use of diesel–electric transmission before 1945. After World War II, by contrast, it gradually became the dominant mode of propulsion for conventional submarines. However, its adoption was not always swift. Notably, the Soviet Navy did not introduce diesel–electric transmission on its conventional submarines until 1980 with its Paltus class. If diesel–electric transmission had only brought advantages and no disadvantages in comparison with a system that mechanically connects the diesel engine to the propeller, it would undoubtedly have become dominant much earlier. The disadvantages include the following:
During its development, Black Mesa received attention from several video game publications. It was featured in articles from Computer Gaming World, PC PowerPlay, and PC Gamer UK magazines. Valve published a news update about the modification on their Steam digital distribution platform in 2007, saying that "We're as eager to play [Black Mesa] here as everyone else." The project was awarded Top Unreleased Mod by video game modification website Mod DB in 2005 and 2006. Mod DB gave the project an honorable mention in their choice of Top Unreleased Mod in 2007. After receiving a development version of Black Mesa in December 2009, PC PowerPlay magazine said that the game's setting "looks, sounds, [and] plays better than ever before". The "subtle" changes from the original Half-Life were said to have a "substantial" overall impact. They also noted the project's "frustrating" then-five-year development time, and current lack of release date, but added that the developers were making progress. After the first major release in 2012, early impressions of the game were very positive, receiving a score of 86/100 on review aggregator Metacritic, based on nine reviews. The game was praised for its high polish, with many critics comparing its quality to that of an official Valve game. Destructoid praised the game for the improvements it made over the original Half-Life, saying it was "something that felt very familiar, [but also] very fresh." Black Mesa won ModDB's Mod of the Year Award for 2012.
Sources: en.wikipedia.org
The decisive victory of Lieutenant-General Bernard Montgomery's Eighth Army over the Germans and Italians at the Second Battle of El Alamein in October–November 1942 turned the tide of the North African war strongly in favour of the Allies, and did much to revive Allied morale. The Rhodesians of the KRRC took part in the battle as part of the 7th Armoured Division under the XIII Corps, forming part of the initial thrust in the southern sector. The Rhodesian Anti-Tank Battery under Major Guy Savory also fought at El Alamein, supporting the Australian 9th Division as part of the XXX Corps. The fighting around "Thompson's Post" between 1 and 3 November was some of the fiercest Rhodesians took part in during the war. Hoping to knock out the Allied anti-tank guns before counter-attacking, the Germans concentrated intense artillery fire on the Australian and Rhodesian guns before advancing 12 Panzer IV tanks towards the weakest point of the Australian line. The Australian six-pounders had been largely disabled by the bombardment but most of the Rhodesian guns remained operational. The Rhodesian gunners disabled two Panzers and seriously damaged two more, compelling an Axis retreat, and held their position until being relieved on 3 November. One Rhodesian officer and seven other ranks were killed and more than double that number were wounded. For his actions at Thompson's Post, Sergeant J A Hotchin received the Distinguished Conduct Medal; Lieutenants R J Bawden and H R C Callon won the Military Cross and Trooper P Vorster the Military Medal.
Pre-adipocytes are undifferentiated fibroblasts that can be stimulated to form adipocytes. Studies have shed light into potential molecular mechanisms in the fate determination of pre-adipocytes although the exact lineage of adipocyte is still unclear. The variation of body fat distribution resulting from normal growth is influenced by nutritional and hormonal status dependent on intrinsic differences in cells found in each adipose depot. Mesenchymal stem cells can differentiate into adipocytes, connective tissue, muscle or bone. The precursor of the adult cell is termed a lipoblast, and a tumor of this cell type is known as a lipoblastoma.
==== Conditions for higher transfer results ==== Nearly complete transfer in systems implementing countercurrent exchange, is only possible if the two flows are, in some sense, "equal". For a maximum transfer of substance concentration, an equal flowrate of solvents and solutions is required. For maximum heat transfer, the average specific heat capacity and the mass flow rate must be the same for each stream. If the two flows are not equal, for example if heat is being transferred from water to air or vice versa, then, similar to cocurrent exchange systems, a variation in the gradient is expected because of a buildup of the property not being transferred properly.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.